Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe I'll get some in the 4's? Pennyland doesn't look like a possibility at this point without a catalyst.
For the abuse we've been through over the years - I really hope you are right.
I've been wrong before
GL
no news, no updates, back to .002
may pick up some more there
Agreed!
Bingo!! Here to stay and loving the ride.
:)
SNDY
blueskies
Welp - It's been fun
SNDY
blueskies
Wolf! Here we go again....News soon call?
Wolf! Wolf! Look a Wolf!
SNDY
blueskies
Good Luck to you Aqua - Hope you make those purchases today!
SNDY
blueskies
I'm sure "news" will be coming - Someday. But I'm gonna go out on the limb here and say that the March Madness call was/is malarkey. JMO - of course. Unfortunately none of us know what's going to happen - which makes it a bit more frustrating but hey it is what it is.
SNDY News never comes on Friday - especially the 13th.....SO I'll see ya all next week.
good luck - stay patient - stay positive.
SNDY
blueskies
Ha ha ha ha - Lovin' my 2's baby. get'em while you can.
Don't know about everybody else but I have a nice little average right about now.
SNDY!
blueskies
Thanks for the inside info. I'm new here.....
False
SNDY
blueskies
mmhmm - SNDY
March Madness beginning or what?
NEWS VERY VERY SOON??
Hello...Is there anybody OUT there? Just nod if you can hear me. Is there anyone at home?
SNDY
blueskies
IMMINENT NEWS?...
...So we've heard
Good Luck
SNDY
blueskies
Let's see .0004 today baby!
SNDY
blueskies
People working OT this weekend! I love it
SNDY
blueskies
SNDY 2/27/15 .0003 84,678,330
Good Luck
blueskies
GREAT POST BLUESKIES....SNDY ALL THE WAY.
SNDY - How We Got Here
Solos Endoscopy completed the Stage 1 Audit with TUV SUD America on Tuesday, February 26, 2013.
June 12, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView® product line in Canada.
Oct 8, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 - 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy's Quality Management System requirements in the audit.
"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy, CEO.
Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe
Nov 7, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease
Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.
"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.
Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally
Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.
April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Blueskies
SNDY
This is a dated statement from SNDY (Jan 2013) but the goals remain the same. It is unfortunate that the certification & licensing process has taken so long but the fact is that it is now completed.
Sounds amazing to me!
Good Luck to you Blaze!
SNDY
blueskies
I actually agree 100% with you on this.
SNDY
blueskies
Ditto!
Same here.
Blueskies
SNDY
haha...thanks 5ACES - In all honesty I am a computer guy - so cutting & pasting didn't take long at all......BUT I do spend too much time here...agreed. :)
Bluekies
Good Luck
SNDY
BTW - if you take into account the number of posts calling for NEWS SOON - I think you've cleared yourself of any insider trading charges...hahaha...
Blueskies
Good luck
SNDY!
So...I'm all about news and positive posts but are we really going to get news SOON? anytime soon? hahaha
Soon = one,two or three months - I think
Very Soon must = one or two months?
Very Very soon must = one month?
Very Very Very soon must = 3 weeks?
Very Very Very Very soon must = 2 weeks?
Very Very Very Very Very soon must = 1 week?
"NEWS SOON! VERY VERY VERY VERY VERY SOON" - this week?
Hahaha - just having fun!
[img]
[/img]
blueskies
SNDY
How about Olea Medical?
http://www.olea-medical.com/
Hope you're still with us mgrego - thanks for the info
Good Luck
SNDY
blueskies
1 for Yes, 2 for No
haha
SNDY
blueskies
Thanks Verticalmojo - Hope you're still around if this does come together.
Looks like the site links have been updated over the past year and a half - but I do recall reading it.
SNDY
blueskies
Hot Stocks:SOLOS ENDOSCOPY (SNDY), AMAZONAS FLORESTAL(AZFL), iHookup Social (HKUP), Minerco Resources (MINE)
Submitted By caddy stocks on January 24, 2015 - 03:30 PM
haha...
SNDY
blueskies
5ACES I posted some SNDY 2014 info too. Most recently November
Good Luck to you
Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease
Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.
"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.
Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally
Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.
April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Blueskies
SNDY
Good Morning Warhead
Today soon would be great! - but the "soon' call is beyond old and think is based solely on an opinion. We all know that.
The " call" had been made months and months ago, now with a so called countdown.......I'll believe it when I see it.
I still remain very positive though and will throughout - I do think an update is in the works. We are due for it!
Shares are being bought and sold in large volumes since Dec. - so we shall see
Good luck to you - great to have the support. More supporters should post jsut for conversation purposes.
It looks like the deletion on posts has subsided since the new positive outlook had come along
Good Luck
Blueskies
855 mil in volume since December.
http://www.nasdaq.com/symbol/sndy/historical
Somebody buying a nice position?
blueskies
SNDY
European & Canadian Expansion coming
SNDY
blueskies
SNDY 2014
Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease
Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.
"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.
Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally
Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.
April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Blueskies
SNDY
SNDY 2013
Solos Endoscopy completed the Stage 1 Audit with TUV SUD America on Tuesday, February 26, 2013.
June 12, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView® product line in Canada.
Oct 8, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 - 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy's Quality Management System requirements in the audit.
"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy, CEO.
Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe
Nov 7, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
blueskies
SNDY
All dug out - let's get back to work.
Don't forget how we got here and where we are going.
SNDY
Blueskies
SNDY
Solos Endoscopy completed the Stage 1 Audit with TUV SUD America on Tuesday, February 26, 2013.
June 12, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView® product line in Canada.
Oct 8, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 - 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy's Quality Management System requirements in the audit.
"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy, CEO.
Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe
Nov 7, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease
Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.
"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.
Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally
Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.
April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Blueskies
SNDY